Drug Database
Back to search

Netherlands· NL-f0e14c216581

Skyrizi 180 mg oplossing voor injectie in een patroon

A risankizumab product containing risankizumab, registered in Netherlands by AbbVie Deutschland GmbH & Co. KG. The same ATC class is registered in 14 of our 19 countries.

ATC L04AC18

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedSkyrizi 180 mg oplossing voor injecti…ATCL04AC18REGISTER NO.NL-f0e14c216581PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about risankizumabAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Risankizumab is registered in 14 of 19 countries.

Countries holding a registration under ATC L04AC18 (risankizumab), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 9 of them publish a price we can compare per daily dose
Search risankizumab products by name

Risankizumab · ATC L04AC18

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of risankizumab costs, country by country.

Normalised to the WHO defined daily dose (1.67 mg), the median price runs from $0.035 in France to $26.21 in Switzerland — a ×755 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Risankizumab · price per daily dose (1.67 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$26.21
  • FR France$0.035
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)
Active substance
RISANKIZUMAB
Manufacturer
AbbVie Deutschland GmbH & Co. KG
Country
Netherlands (NL)
ATC code
L04AC18
ATC class
Risankizumab
Defined daily dose
1.67 mg, P
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/19/1361

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

75 interactions on record for risankizumab.

Graded by severity as the source publishes them — 27 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check risankizumab against other medicinesHow interaction checks work

Risankizumab · interactions on record

75 records

  • 27 severe
  • 41 moderate
  • 7 minor

Most severe, free to view

  • CladribineL01BB04severe
  • Talimogene laherparepvecL01XL02severe
  • Talimogen laherparepvecL01XX51severe
  • LeflunomidL04AA13severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Risankizumab in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All risankizumab products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

  • United Kingdom (Northern Ireland) · Skyrizi
  • Iceland · Skyrizi
  • Liechtenstein · Skyrizi
  • Norway · Skyrizi

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/89c65635-8603-4748-9a7b-9e9b92de393a
GET /v1/drugs/89c65635-8603-4748-9a7b-9e9b92de393a?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Oplossing voor injectie",
  "route": "Subcutaan gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/skyrizi-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Risankizumab",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp132187",
  "excipients": [
    "AZIJNZUUR (E 260), GECONCENTREERD",
    "NATRIUMACETAAT 3-WATER (E 262)",
    "POLYSORBAAT 20 (E 432)",
    "TREHALOSE (Alpha, Alpha-)  2-WATER",
    "WATER VOOR INJECTIE"
  ],
  "substances": [
    "RISANKIZUMAB"
  ],
  "leaflet_url": null,
  "authorised_at": "2024/07/24",
  "procedure_number": "EMEA/H/C/004759",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/19/1361",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about risankizumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console